Jump to content

Choose locationChoose Location
  • Sign in or Enroll
    • Open I want to choose my medical group or hospital
    • Clear my location
Change Location

We've expanded your view

You are now viewing all services in the Sutter Health network. You can change your location above to narrow your view to a medical group, hospital, city or zip.
Sutter Health
  • Video Visits
  • Find Doctors
  • Find Locations
  • Treatments & Services
  • Locations
  • Sign in or Enroll
    • Video Visits
    • Find Doctors
    • Find Locations
    • Treatments & Services
    • COVID-19 Resources
    • Pay a Bill
    • Symptom Checker
    • Get Care Today
    • Diseases & Conditions
    • Health & Wellness
    • Classes & Events
    • Research & Clinical Trials
    • For Patients
    • About Sutter Health
    • Giving
    • Volunteering
    • Careers
    • News
    • For Medical Professionals
    • Other Business Services
Close Search
  • Home
  • Research
  • Investigators
  • Ari Baron
Content

Investigator Ari Baron, M.D.

Ari Baron, M.D.

View profile  

Ari D. Baron, M.D., is Chief of the Division of Hematology Oncology at California Pacific Medical Center (CPMC), and Associate Clinical Professor of Medicine at UCSF. His practice has been at CPMC for over 20 years.

Dr. Baron is the Medical Director of Clinical Oncology Research at CPMC, and the Chair of the Science Committee for Sutter Health Cancer Research Group. He also serves on the Board of Governor’s for South West Oncology Group (SWOG), one of the largest National Cancer Institute cooperative cancer research groups.

Dr. Baron's main focus is in clinical research, where he has helped develop new medications for cancer patients across a broad array of diseases. He specializes in gastrointestinal cancers of the colon, liver, and pancreas, and urologic malignancies of the prostate and bladder.

Dr. Baron was one of the clinical oncology leads at Sutter Health enrolling patients to the TAPUR™ study, a national, prospective, non-randomized clinical trial determining the safety and efficacy of approved, targeted anticancer drugs.

He has co-authored numerous peer-reviewed publications in high-impact journals such as The New England Journal of Medicine, The Lancet, and the Journal of the American Medical Association.

These studies have helped secure FDA approval for treatments such as bevacizumab (Avastin®) a drug that inhibits blood vessels from supplying cancers and was approved for the treatment of colon cancer, and nivolumab (Opdivo®) an immunotherapy for bladder cancer.


Sutter Health Research Enterprise
2100 Webster Street Suite 225
San Francisco, CA, 94115
(415) 923-3012  
abaron@phoamd.com

Primary Research Interests

  • Anal Cancer
  • Biliary Cancer
  • Breast Cancer
  • Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Liver Cancer
  • Lung Cancer
  • Molecular/Rare Tumor
  • Pancreatic Cancer
  • Prostate Cancer
  • Renal Cancer
  • Skin Cancer/Melanoma
  • Solid Tumors

Related Clinical Trials

Adjuvant (Alliance A021502)

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Adjuvant (BMS CheckMate 9DX)

A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Investigators: Ari Baron M.D., Gauri Kelekar MD

Status: Active, Recruiting

Adjuvant (NRG GI005) Temporarily on Hold

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Investigator: Ari Baron M.D.

Status: Active, Not Recruiting

Adjuvant (SWOG S1418/BR006)

Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Locally Advanced (CheckMate73L)

A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Investigators: Ari Baron M.D., Caroline Behler MD, Kevin Kim MD, Alan Kramer MD, Wei Wang MD

Status: Active, Recruiting

Locally Advanced (ECOG-ACRIN EA2165)

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Locally Advanced (Fibrogen Pancreas)

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy in Locally Advanced Pancreatic Cancer

Investigators: Ari Baron M.D., Gauri Kelekar MD

Status: Active, Recruiting

Locally Advanced (Lilly JVDE) Temp Enrollment Hold

Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

Investigator: Ari Baron M.D.

Status: Active, Not Recruiting

Locally Advanced or Metastatic (Alliance A021602)

Cabozantinib in Treating Patients with Neuroendocrine Tumors previously treated With Everolimus. Locally Advanced, Metastatic, or can't be removed by surgery

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Locally Advanced or Metastatic (AstraZeneca TOPAZ-1)

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Locally Advanced or Metastatic (Genentech GO27983)

Ipatasertib or Apitolisib + Abiraterone Acetate Vs Abiraterone alone in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Investigators: Ari Baron M.D., Milana Dolezal MD

Status: Active, Recruiting

Locally Advanced or Metastatic (LungMAP Screening Study)

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Locally Advanced or Metastatic (SWOG S1613)

Trastuzumab&Pertuzumab or Cetuximab&Irinotecan Hydrochloride in Treating Patients w/Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Locally Advanced or Metastatic (Vedanta)

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer (Consortium-IO)

Investigators: Ari Baron M.D., Gauri Kelekar MD

Status: Active, Recruiting

Metastatic (ECOG-ACRIN EA8153)

Abiraterone Acetate & Antiandrogen Therapy +/- Cabazitaxel& Prednisone in Treating Pts W/Metastatic, Castration-Resistant Prostate Ca. Prev. Treated W/Docetaxel

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Metastatic (NRG GI004/SWOG-S1610)

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Metastatic (SWOG S1800A) (LungMap Sub-Study) Closed to Accrual

Ramucirumab & Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Trmt Trial)

Investigator: Ari Baron M.D.

Status: Active, Not Recruiting

Metastatic (SWOG S1900A) (LungMap Sub-Study) Temp Enrollment Hold

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer

Investigator: Ari Baron M.D.

Status: Active, Not Recruiting

Metastatic (SWOG S1900B) (LungMap Sub-Study)

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Metastatic (SWOG S1900C) (Lung Map Sub Study) Closed to Accrual

PhII Study of Talazoparib + Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations

Investigator: Ari Baron M.D.

Status: Active, Not Recruiting

Metastatic (SWOG S2001)

Testing addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Tx for Pts w/Pancreatic Cancer That Has Spread w/Inherited BRCA Mutations

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Metastatic or Recurrent (QED QBGJ398-301 Proof)

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Investigators: Ari Baron M.D., Bertrand Tuan MD

Status: Active, Recruiting

Neoadjuvant (Alliance A021806)

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Neoadjuvant (ECOG-ACRIN EA8143)

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Investigator: Ari Baron M.D.

Status: Active, Recruiting

Neoadjuvant (NRG GI002) Temp Enrollment Hold

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Investigator: Ari Baron M.D.

Status: Active, Not Recruiting

Rare Tumor Type (SWOG S1609)

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Investigator: Ari Baron M.D.

Status: Active, Recruiting

The Sutter Health Network of Care
Expertise to fit your needs
Primary Care

Check-ups, screenings and sick visits for adults and children.

Specialty Care

Expertise and advanced technologies in all areas of medicine.

Emergency Care

For serious accidents, injuries and conditions that require immediate medical care.

Urgent Care

After-hours, weekend and holiday services.

Walk-In Care

Convenient walk-in care clinics for your non-urgent health needs.

About Sutter

  • About Our Network
  • Annual Report
  • Awards
  • Community Benefit
  • Contact Us
  • News
  • Giving
  • Find Care

  • Birth Centers
  • Care Centers
  • Emergency Rooms
  • Hospitals
  • Imaging
  • Labs
  • Surgery Centers
  • Urgent Care
  • Walk-In Care
  • View All >
  • Featured Services

  • Behavioral Health
  • Cancer Services
  • Family Medicine
  • Home Health and Hospice
  • Orthopedics
  • Pediatrics
  • Pregnancy
  • Primary Care
  • Women's Health
  • View All >
  • Patient Resources

  • Accepted Health Plans
  • Classes and Events
  • Estimate Costs
  • Flu Resources
  • Health and Wellness
  • Medical Records
  • Medicare
  • My Health Online
  • Pay a Bill
  • Symptom Checker
  • Our Team

  • For Employees
  • Physician Careers
  • Recruiting Events
  • Sutter Careers
  • Vendors
  • Volunteers
    • ADA Accessibility
    • Contact
    • Privacy
    • Do Not Sell My Personal Information

    • LinkedIn Opens new window
    • YouTube Opens new window
    • Facebook Opens new window
    • Twitter Opens new window
    • Glassdoor Opens new window
    • Instagram Opens new window

    Copyright © 2021 Sutter Health. All rights reserved. Sutter Health is a registered trademark of Sutter Health ®, Reg. U.S. Patent & Trademark office.

    Cookie Policy

    We use cookies to give you the best possible user experience. By clicking on "Accept Cookies", closing this pop-up banner or by continuing to use the site, you agree to the use of cookies. Privacy Policy   Cookie Preferences